Novel Agents and Strategies in Lung Cancer
Oncology Today with Dr Neil Love
00:00
Tarlatumab Approval: Insights from the Delphi 301 Study
This chapter covers the recent approval of Tarlatumab, a bispecific T cell engager, focusing on its clinical trial results from the Delphi 301 study. With a reported response rate of 40% and critical metrics like duration of response and median overall survival, the chapter also examines the dosing strategies and comparisons within the trial.
Transcript
Play full episode
